RPRX Royalty Pharma Plc Class A

Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025 at 3:20 p.m. ET.

The webcast will be accessible from Royalty Pharma’s “Events” page at . The webcast will also be archived for a minimum of thirty days.

About Royalty Pharma

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 17 development-stage product candidates. For more information, visit .   

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6637



EN
04/09/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Royalty Pharma Plc Class A

 PRESS RELEASE

Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Hea...

Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025 at 3:20 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at . The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a ...

 PRESS RELEASE

Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured N...

Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $2.0 billion of senior unsecured notes, comprised of the following (collectively, the “Notes”): $600 million of 4.450% Notes due 2031 (the “2031 Notes”);$900 million of 5.200% Notes due 2035 (the “2035 Notes”); and$500 million of 5.950% Notes due 2055 (the “2055 Notes”). The Notes will be guaranteed on a senior unsecured basis by Royalty Pharma Holdings Ltd and Royalty Pharma Manager, L...

Moody's Ratings assigns Baa2 rating to Royalty Pharma's new senior uns...

Moody's Ratings (Moody's) assigned Baa2 ratings to the new backed senior unsecured notes of Royalty Pharma plc ("Royalty Pharma"). There are no changes to Royalty Pharma's existing ratings including the Baa2 senior unsecured ratings. The outlook remains unchanged at stable. The proceeds from the o...

 PRESS RELEASE

Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agree...

Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related DiseaseAdditional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related Disease NEW YORK and WALTHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Zenas BioPharma, Inc. (Nasdaq: ZBIO) today announced that Royalty Pharma will provide up to $300 million in fundi...

 PRESS RELEASE

Royalty Pharma to Acquire Royalty Interest in Amgen’s Imdelltra for up...

Royalty Pharma to Acquire Royalty Interest in Amgen’s Imdelltra for up to $950 Million Imdelltra is a first-in-class immunotherapy for the treatment of extensive-stage small cell lung cancer (ES-SCLC) marketed by AmgenRoyalty Pharma to pay $885 million upfront; BeOne Medicines to retain a $65 million option to sell additional portion of its royalty NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in Amgen’s Imdelltra, a first-in-class DLL3 targeting bispecific T-cell engager (BiTE), from BeOne Medicines ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch